Readystate Asset Management LP acquired a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 295,038 shares of the company’s stock, valued at approximately $684,000. Readystate Asset Management LP owned 0.24% of Mersana Therapeutics as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Fox Run Management L.L.C. bought a new position in shares of Mersana Therapeutics in the third quarter worth about $28,000. Bayesian Capital Management LP bought a new position in Mersana Therapeutics during the fourth quarter valued at approximately $28,000. Victory Capital Management Inc. purchased a new position in Mersana Therapeutics during the 4th quarter valued at approximately $30,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at approximately $37,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Mersana Therapeutics during the 4th quarter valued at approximately $37,000. Institutional investors own 93.92% of the company’s stock.
Mersana Therapeutics Trading Down 5.1 %
Shares of MRSN stock traded down $0.18 on Thursday, reaching $3.34. 1,273,915 shares of the company’s stock were exchanged, compared to its average volume of 2,205,871. Mersana Therapeutics, Inc. has a 52 week low of $0.80 and a 52 week high of $9.62. The company has a current ratio of 3.36, a quick ratio of 3.36 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $405.14 million, a PE ratio of -2.23 and a beta of 1.50. The company’s fifty day simple moving average is $4.48 and its 200 day simple moving average is $2.89.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on MRSN shares. BTIG Research upgraded Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Thursday, February 29th. Truist Financial upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Thursday, February 29th. Wedbush upgraded Mersana Therapeutics from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $2.00 to $7.00 in a report on Thursday, February 29th. Guggenheim upgraded Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $7.00 target price for the company in a report on Thursday, February 29th. Finally, Robert W. Baird lifted their target price on Mersana Therapeutics from $1.00 to $5.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.29.
View Our Latest Report on MRSN
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Read More
- Five stocks we like better than Mersana Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Comprehensive PepsiCo Stock Analysis
- What is the Dogs of the Dow Strategy? Overview and Examples
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Are Dividend Champions? How to Invest in the Champions
- Bear Market Funds to Watch This Year
Want to see what other hedge funds are holding MRSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report).
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.